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Objective—To evaluate in women with twin gestation the relationship between 17-
hydroxyprogesterone caproate (17-OHPC) concentration and gestational age at delivery and select
biomarkers of potential pathways of drug action.
Study Design—Blood was obtained between 24–28 weeks (epoch 1) and 32–35 weeks (epoch
2) in 217 women with twin gestation receiving 17-OHPC or placebo. Gestational age at delivery
and concentrations of 17-OHPC, 17-hydroxyprogesterone, progesterone, C-reactive protein (CRP)
and corticotrophin releasing hormone were assessed.
Results—Women with higher concentrations of 17-OHPC delivered at earlier gestational ages
than women with lower concentrations (p<0.001). Women receiving 17-OHPC demonstrated
significantly higher (p=0.005) concentrations of CRP in epoch 1 than women receiving placebo
but CRP values were similar in epoch 2 in both groups. A highly significant (p<0.0001) positive
relationship was observed between 17-OHPC concentration and progesterone and 17-
hydroxyprogesterone concentrations at both epochs. CRH concentrations did not differ by
treatment group.
Conclusion—17-OHPC may adversely impact gestational age at delivery in women with twin
gestation.
Keywords
17-hydroxyprogesterone caproate (17-OHPC); pharmacodynamics; twin gestation
Introduction
17-hydroxyprogesterone caproate (17-OHPC) reduces the rate of preterm birth in women
with a singleton gestation and a prior preterm birth.1 Despite widespread clinical use of this
agent the mechanism of action and target organ of this therapy are not known. Knowledge of
the mechanism of action and target tissue(s) of this therapy would enable a better
understanding of preterm labor, its etiology and possible development and refinement of
prevention strategies. The purpose of this study was to define in a cohort of women with
twin gestation the relationship between 17-OHPC concentration and gestational age at
delivery. These women were participants in a placebo - controlled randomized clinical trial
to evaluate the efficacy of 17-OHPC in preventing preterm birth.2 Although treatment
proved ineffective in twins, blood samples collected during 17-OHPC treatment allowed an
evaluation of the relationship between plasma drug concentration and gestational age at
delivery. Additionally we evaluated the relation between plasma 17-OHPC concentration
and select gestational hormones as well as biomarkers of other potential pathways of drug
action, C-reactive protein (CRP) as a marker of systemic inflammation and Corticotropin
Releasing Hormone (CRH) as a marker of the endocrine pathway involved in human
parturition.3,4
MATERIALS AND METHODS
Patients and Drug Administration
This was a planned ancillary study to the MFMU Network randomized trial of women with
twins who were receiving either intramuscular 17-hydroxyprogesterone caproate or
placebo.2 A total of 661 women with twins were recruited for the randomized trial. Subjects
received masked weekly injections of either 250 mg 17-OHPC in 1 ml castor oil or 1 ml
castor oil alone from the time of enrollment (16 0/7 weeks – 20 6/7 weeks) until 34 weeks 6
days or until delivery, whichever came first.
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Consenting subjects were informed that two blood samples would be taken, one between
24–28 weeks (epoch 1) and one between 32–35 weeks (epoch 2) for determination of
progesterone, 17-hydroxyprogesterone, 17-OHPC, CRP and CRH concentrations. The
timing of epoch 1 was intended to obtain a blood sample after a minimum of four injections
would have been administered to allow steady state to be reached. The timing of the second
epoch was intended to evaluate gestational age related changes in pharmacodynamic
parameters.
Sample Analysis
For measurement of 17-OHPC, progesterone, 17-hydroxyprogesterone and CRP, blood was
collected in 10 ml tubes with anticoagulant and centrifuged within one hour at 2500 rpm for
10 minutes. The supernatant plasma was aliquoted to 1 ml tubes and was frozen at −70 ° C
until analysis. Quantification of 17-OHPC, progesterone and 17-hydroxyprogesterone
concentration was performed using high performance liquid chromatography with tandem
mass spectrometry (LC-MS). The assay methodology has been reported elsewhere.5 The
lower assay limit of detection for 17-OHPC was 1 ng/ml, inter and intra assay variability at
10 ng/ml was 7.9% and 5.2% respectively. For progesterone and 17-hydroxyprogesterone,
the lower limit of detection were 2 ng/ml and 1 ng/ml respectively. The inter and intra assay
variabilities for progesterone (5 ng/ml) were 7.7 and 8.4 percent respectively and 12.3 and
9.5 percent for 17-hydroxyprogesterone. At the time of the analysis, the analyst and the
clinical centers involved in recruitment were blinded to the treatment assignment.
CRP in maternal plasma was measured with a commercially available ELISA kit (Alpha
Diagnostic International, San Antonio, TX), with a coefficient of variation of 3.0%. Separate
linear standard curves were generated for each sample plate, and those values that were
greater than the maximum concentration of the standard were repeated after progressive
dilutions.
For CRH measurements, blood was collected in a 5 ml chilled tube with EDTA and
aprotinin (500KIU/ml blood), centrifuged at 2500 rpm for 10 minutes at 4° C. Aliquots of
the supernatant were then transferred to a polypropylene tube then stored at −70° C until
analyzed. CRH peptide was extracted from plasma using Linton’s method.6 The dried
extracts were resuspended in 0.5 ml, 0.05mol/L phosphate buffer, pH 7.3, containing 5.8 g/L
NaCl, 9.5 g/L ethylenediamine tetraacetate, 1.0 g/L NaN3, and 1 mL/L Triton and
transferred to a storage vial. Vials were rinsed with another 0.5 ml buffer to recuperate
residual peptide. Pooled aliquots of the reconstituted extracts were stored at −80° C and
assayed in batches. Each methanol extraction consisted of spiked plasma controls from a
healthy male donor. Purified, CRH peptide (Peninsula Laboratories) was adjusted to 5 ng/ml
and 2.5 ng/ml in the donor plasma to serve as both assay controls and as an extraction
reference standard. Because methanol extraction efficiency varies from batch to batch, all
CRH test sample values were adjusted accordingly. For example, the 5 ng control following
extraction was tested at 4.5 ng CRH (an extraction efficiency of 90%, assuming the
detection method is complete). In this case, all test samples would be adjusted up by a factor
of 1.11 in this batch to compensate for incomplete CRH extraction.
For the enzyme immunoassay, EIA, (Peninsula Laboratories, San Carlos, CA), anti-CRH
antibodies were plated on a 96-well plate. In each well, a known concentration of
biotinylated tracer was co-incubated for 2 hours at 21–23°C with anti-human CRH and 50ul
of sample. Following a wash step, streptavidin-conjugated horseradish peroxidase was
added to each well and the incubation continued for 1 hour. The wells were again washed
and the substrate, tetramethyl benzidine dihydrochloride was added. After 45 minutes, the
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reaction was stopped with 2 N HCL and the absorbance was read at 450 nm. The data were
plotted against a CRH standard S-shaped curve on a semi-log plot, which was provided as
an Excel (Microsoft, Redmond, WA) spreadsheet by the Bachem Group, a member of
Peninsula Labs. In our laboratory, the intra and inter-assay variability of the CRH EIA is
comparable to other commercial immunoassay kits, ≤10%.
Statistical Analysis
For all analyses, we excluded women who did not receive all of their scheduled injections
up to the time of the first blood draw (epoch 1). For analyses involving data from the second
blood draw we also excluded women who did not receive all of their injections between the
first and second blood draw. For analyses related to gestational age at delivery, we excluded
all women who did not receive all their scheduled injections up to the time of delivery or
until 35 weeks gestation. Rate of change for each analyte was calculated as the difference
between the first and second epoch value divided by time elapsed in weeks between blood
draws. Chi-square and Wilcoxon tests were used to make univariable two-group
comparisons for categorical and continuous variables respectively. Spearman rank
correlation coefficients were calculated to assess the pairwise correlation between
continuous variables. Proportional hazards regression was used to analyze the relationship
between the analytes and gestational age at delivery, adjusting for gestational age at the time
of blood draw, as well as for race/ethnicity and BMI which may impact plasma 17-OHPC
concentrations (7). Indicated deliveries were censored at the time of delivery. For the
multivariable analysis, monochorionic-diamniotic pregnancies were excluded because
placentation, progesterone levels and endogenous steroid hormones could affect gestational
age at delivery compared with dichorionic-diamniotic pregnancies. For the proportional
hazards models assessing gestational age at delivery versus CRP and versus progesterone,
17-OHPC was also included as a covariate because 17-OHPC concentration increases with
gestational age as a consequence of greater number of castor oil depots seen with weekly
injections. Generalized R-squared values were calculated to estimate the proportion of
explained variation. Scatter plots were used to demonstrate relationships visually. For all
statistical tests, nominal two-sided p-values are reported with statistical significance defined
as a p-value < 0.05. No corrections were made for multiple comparisons. SAS Software
(SAS Institute, Cary, North Carolina) was used for these analyses.
RESULTS
Characteristics of the Study Population
Among the 661 subjects enrolled in the main trial, 217 agreed to the study, received all
scheduled injections and had blood drawn at epoch 1;118 in the placebo group and 99 in the
17-OHPC group. Table 1 compares demographic parameters of these subjects at enrollment
according to treatment group. Gestational age at delivery is also provided. There were no
significant differences between women treated with 17-OHPC or placebo. A total of 92 of
these women in the placebo group and 72 in the 17-OHPC group had received all of their
injections and had a blood drawn by epoch 2. A median of seven injections had been
administered by epoch1 and 14 by epoch 2 in each of the two groups. The gestational age at
which blood samples were obtained was similar in the two treatment groups at the first
sampling but there was a significant (p=0.04) difference of four days in gestational age at
the second blood sampling.
Comparison of plasma CRH, CRP, progesterone and 17-hydroxyprogesterone
concentrations by treatment group
Table 2 compares plasma CRH, CRP, progesterone, 17-hydroxyprogesterone concentrations
at each of the two epochs and the rate of change of these hormones between the two
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sampling times according to treatment group. The plasma concentrations of 17-OHPC at
each epoch are also provided.
CRH concentrations and the rate of change of CRH concentration were not significantly
different. CRP was significantly higher in epoch1 in the 17-OHPC group when compared
with placebo. At epoch 2 however, plasma CRP concentrations were similar in the two
treatment groups. Progesterone and 17-hydroxyprogesterone concentrations were not
significantly different at epoch 1 and 2 between the 17-OHPC and placebo groups and
neither were the rates of change. Concentrations of 17-OHPC increased slightly from epoch
1 to epoch 2. The drug was not detected in women receiving placebo.
Relationship of 17-OHPC with selected biomarkers of preterm birth
We evaluated the relationship between 17-OHPC concentration and CRH, CRP,
progesterone and 17-hydroxy-progesterone. Table 3 summarizes these relationships. A
highly significant positive monotonic relationship is seen between 17-OHPC concentration
and progesterone concentration as well as 17-OHPC concentration and 17-
hydroxyprogesterone at both sample times. These relationships at epoch 2 are depicted in
Figure 1 for progesterone and its metabolite 17-hydroxyprogesterone. The rate of change in
progesterone concentration likewise is positively related to the concentration of 17-OHPC.
Despite the fact that CRP was significantly higher in the 17-OHPC group compared with the
placebo group in epoch 1, we could not demonstrate a concentration relationship between
17-OHPC and CRP either at epoch 1 or epoch 2 or over the rate of change between epoch 1
and 2.
There was no correlation between CRH concentration and 17-OHPC concentration at
epoch1; however, at epoch 2 CRH was significantly correlated with the concentration of 17-
OHPC (Spearman’s ρ=0.31, p=0.02) as was the rate of rise of CRH (ρ=0.34, p=0.01) and
these relationships are depicted in Figure 2.
Relationship of plasma 17-OHPC, CRH, CRP, progesterone and 17-hydroxy-progesterone
to gestational age at delivery
We evaluated the relationship of the five plasma analytes (17-OHPC, CRP, CRH, 17-
hydroxyprogesterone and progesterone) at the first sampling period to the outcome of
gestational age at delivery in the placebo and treatment groups in a proportional hazards
model, adjusting for confounders. The relationship between each of these analytes and
gestational age of delivery is summarized in Table 4. In the placebo group no significant
relationship was identified between the analytes and gestational age at delivery. Among the
17-OHPC treated group none of the analytes was significantly related to gestational age of
delivery, except for 17-OHPC concentration which demonstrated a highly significant
negative relation to gestational age at delivery. Figure 3 demonstrates the relationship
between 17-OHPC concentration and gestational age at delivery. When adjusted for
gestational age at the time of blood draw, race/ethnicity and BMI (Table 4) the hazard ratio
was highly significant (1.14, p = 0.001, R2= 0.49).
We compared characteristics of those women who received all their injections with those
who did not receive all their injections for reasons of non-compliance. We found no
significant differences in maternal age, BMI, parity or number of prior preterm births. We
also dichotomized 17-OHPC concentrations (above and below the 75th percentile ) to assure
that those women with higher concentrations did not have some characteristic that might
also be a risk factor for preterm birth. We found no significant difference between high 17-
ohpc concentration group (≥14ng/ml) and the lower concentration(<14 ng/ml) group in the
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frequency of potential risk factors of preterm birth like AA race, any prior preterm birth or
monochorionic placentation.
Discussion
This is the first report of the relationship between plasma 17-OHPC concentrations and
gestational age at delivery.7 The current study provides considerable insight into the drug’s
impact on selected markers of preterm birth and on endogenous hormones. The most
intriguing findings of this study relate to the relationship of 17-OHPC and gestational age at
delivery particularly with evidence of early systemic inflammation in women receiving 17-
OHPC. Adjusting for 17-OHPC in the proportional hazards regression, as well as race/
ethnicity, BMI and gestational age at blood draw, CRP did not show a significant
relationship with gestational age at delivery (p=0.06). In addition, we could not demonstrate
a relationship between 17-OHPC and CRP concentrations suggesting that the negative
relationship between gestational age at delivery and 17-OHPC concentrations may not be
primarily attributable to an effect of the elevated CRP. Labor and parturition are recognized
as inflammatory states; therefore, it is possible that the elevated CRP concentrations
represent a concomitantly activated parturitional process rather than an antecedent cause of
the parturitional process. Although CRP was significantly higher in the 17-OHPC treated
group compared with the placebo group was significantly higher in the 17-OHPC treated
group compared with the placebo group at 24–28 weeks, by 32–35 weeks the CRP
concentrations were similar in the two groups. The apparent negative association of 17-
OHPC concentration and gestational age at delivery was not associated with significant
difference in gestational age at delivery in parent study or in the ancillary study reported
here 2. In the parent study, delivery or fetal death before 35 weeks occurred in 41.5% of
pregnancies in the 17-OHPC group and 37.3% of those in the placebo group (relative risk,
1.1; 95% confidence interval [CI], 0.9 to 1.3). Yet, among these same subjects we were able
to demonstrate a highly significant negative relationship between 17-OHPC concentrations
and gestational age at delivery. A similar relationship is seen between 17-OHPC and
progesterone concentrations. Although mean progesterone concentrations did not differ
significantly between treatment groups a very strong relationship was seen between 17-
OHPC and progesterone concentrations. These observations suggest that the negative
association between 17-OHPC concentration and gestational age at delivery may impact a
limited subset of subjects with twin gestation. For example, women with specific
progesterone receptor (PR) genotype polymorphisms may be at particular risk. Manuck et
al9 reported that certain PR single nucleotide polymorphisms (SNPs) were associated with
higher risk of preterm birth in response to 17-OHPC. Whether PR SNPs were responsible
for the inverse relationship between 17-OHPC concentration and gestational age at delivery
noted in this study is unknown as we did not determine PR polymorphisms in this group.
The inverse relationship between 17-OHPC concentration and gestational age at delivery
and the elevated CRP in the 17-OHPC group in twins should not be extrapolated to singleton
gestations since the drug concentration and pregnancy outcome relationships may be
different. Clearly additional pharmacologic data may help to define the relationship between
progesterone supplementation and pregnancy outcome in twins. Whether these relationships
have applicability to singleton gestation is unknown.
We also found several interesting and perhaps clinically relevant associations with 17-
OHPC use. First we found a very strong relationship between 17-OHPC and progesterone
concentrations even though plasma progesterone concentrations were, overall, not
significantly different between the two treatment groups. This can be explained by the fact
that several factors affect progesterone concentrations and the impact of 17-OHPC on
plasma progesterone concentration is relatively small compared with these other factors. In
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human liver microsomes, progesterone competes with metabolism of 17-OHPC.10
Progesterone and 17-OHPC are both metabolized by CYP 3A4 and it is likely that the
increase in progesterone concentrations is due to some degree of inhibition with the
metabolizing enzyme.11 In monkeys, 17-OHPC clearly increases progesterone
concentrations12 but in human studies, including the current one, median values are
increased with 17-OHPC treatment but only modestly.13,14 Whether the increase in
progesterone concentrations has a benefit on pregnancy outcome cannot be determined at
this time. The fact that progesterone supplementation seems to reduce preterm birth in
certain subsets of at-risk women suggests that an increase in progesterone concentrations is
central to any beneficial effect of progestin supplementation. Plasma progesterone
concentrations do not reflect tissue concentrations of progesterone thus the positive impact
of 17-OHPC on progesterone concentration may be much greater at the tissue level than at
the plasma level and may account for any benefit attributable to this therapy.
The strength of the relationship between CRH and 17-OHPC concentration is relatively
modest and, in fact, 17-OHPC is positively not negatively associated with CRH
concentration. It is important to evaluate the relationship between CRH and 17-OHPC
because CRH increases in both term and preterm births weeks prior to delivery. Since 17-
OHPC is positively related to CRH concentration, this could imply a potential adverse effect
of 17-OHPC treatment. Although the dose relationship is weak, it is possible that 17-OHPC
has a clinically relevant impact on CRH and gestational age at delivery. In fact, we have
previously demonstrated that although BMI has a very modest relationship (r= −0.28 to
−0.34) to 17-OHPC concentration, when BMI is modeled against plasma 17-OHPC
concentrations, it has a very dramatic effect on plasma concentrations 15. Clearly additional
data are required to reach any meaningful conclusion about this intriguing relationship
especially in singleton gestation.
In conclusion, we have demonstrated, for the first time, the relationship between 17-OHPC
concentration and gestational age at delivery in women with twin gestation. This may define
more clearly the potential risks and benefits of this therapy. We have demonstrated that
among women with twin gestation higher plasma concentrations of 17-OHPC are associated
with a shorter gestational age at delivery than lower concentrations of 17-OHPC. Women
receiving 17-OHPC have higher CRP values than women receiving placebo but no dose
relationship between CRP and 17-OHPC is apparent. We have also demonstrated a strong
dose-relationship between 17-OHPC and progesterone and a modest but significant
relationship between 17-OHPC and CRH especially the rate of rise of CRH. The findings
above apply to women with twin gestation and cannot be assumed to pertain in women with
singleton gestation. More research is required to define the mechanism of action of 17-
OHPC and to optimize the dose of 17-OHPC especially in singleton gestation where
efficacy has been demonstrated. An urgent need exists to identify subsets of women who
may most benefit from this therapy and to define those who might be harmed by this
therapy.
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Relationship of 17-OHPC concentration with progesterone and 17-hydroxyprogesterone in
epoch 2. Spearman correlation coefficient = 0.46 (p<0.0001) for 17-OHPC vs progesterone
and Spearman correlation coefficient = 0.29 (p=0.01) for 17-OHPC vs 17-
hydroxyprogesterone.
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Relationship of 17-OHPC to CRH concentration in epoch 2 and to the rate of change of
CRH. Spearman correlation coefficient =0.31 (p=0.02) for 17-OHPC vs CRH concentration
in epoch 2 and Spearman correlation coefficient = 0.34 (p=0.01) for 17-OHPC vs rate of
change of CRH.
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Scatterplot of 17-OHPC concentration and gestational age at delivery.
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